To date, studies on breast, colon, prostate, and ovarian cancers have shown the possibilities of circulating miRNAs as diagnostic and prognostic markers for each cancer [ 102– 105].
Our and Fridlender et al's findings on the recruitment and activation of TANs by IL-1β and TGF-β blockade shed some light on the possibility of conversion of circulating protumour neutrophils to intratumoural antitumour neutrophils (Fridlender et al, 2009).
We evaluated the possibility of using circulating vascular endothelial growth factor (VEGF) and soluble adhesion molecules as reliable predictors of native arteriovenous (AV) fistula thrombosis in chronic hemodialysis (HD) patients.
One of these is the possibility of increased circulating tumour cells postoperatively [ 49, 50].
Ditkoff et al (1996) were the first to investigate the possibility of detecting circulating malignant thyroid cells using RT PCR.
This inverse correlation supports the possibility of using circulating miRNAs as fingerprints for a diagnostic and prognostic evaluation of the disease [ 29].
Ditkoff et al (1996) first investigated the possibility of detecting circulating malignant thyroid cells using an RT PCR reaction for the detection of Tg-mRNA; this could serve as an indicator of postoperatively present metastatic thyroid cancer.
To explore the possibility of identifying circulating candidate protein markers in rare diseases, we applied an affinity-proteomics approach to generate proteomic signatures in blood of muscular dystrophy patients and controls.
Samples from individuals on drug holidays for longer than 2 weeks before the time of the study were excluded because of the possibility of the reversion of circulating mutant genotypes [ 15, 16].
The findings of Li et al. highlight the possibility that the measurement of circulating prostaglandins might be useful in cancer screening and prevention, but naturally there are caveats (Li et al., 2015).
